Portal de Periódicos da CAPES

Selegiline and mortality in Parkinson's disease

1996; Wiley; Volume: 40; Issue: 6 Linguagem: Inglês

10.1002/ana.410400605

1531-8249

C. Warren Olanow, Stanley Fahn, J. William Langston, James Godbold,

Neurological diseases and metabolism

Annals of NeurologyVolume 40, Issue 6 p. 841-845 Point of View Selegiline and mortality in Parkinson's disease Dr. C. W. Olanow MD, FRCP(C), Corresponding Author Dr. C. W. Olanow MD, FRCP(C) Department of Neurology, Mount Sinai Medical Center, New York, NYDepartment of Neurology, Mount Sinai Medical Center, 1 Gustave Levy Place, Box 1107, New York, NY 10029Search for more papers by this authorS. Fahn MD, S. Fahn MD Department of Neurology, Columbia University, New York, NYSearch for more papers by this authorJ. W. Langston MD, J. W. Langston MD Parkinson Institute, Santa Clara, CASearch for more papers by this authorJ. Godbold PhD, J. Godbold PhD Department of Community Medicine, Mount Sinai School of Medicine, New York, NYSearch for more papers by this author Dr. C. W. Olanow MD, FRCP(C), Corresponding Author Dr. C. W. Olanow MD, FRCP(C) Department of Neurology, Mount Sinai Medical Center, New York, NYDepartment of Neurology, Mount Sinai Medical Center, 1 Gustave Levy Place, Box 1107, New York, NY 10029Search for more papers by this authorS. Fahn MD, S. Fahn MD Department of Neurology, Columbia University, New York, NYSearch for more papers by this authorJ. W. Langston MD, J. W. Langston MD Parkinson Institute, Santa Clara, CASearch for more papers by this authorJ. Godbold PhD, J. Godbold PhD Department of Community Medicine, Mount Sinai School of Medicine, New York, NYSearch for more papers by this author First published: December 1996 https://doi.org/10.1002/ana.410400605Citations: 25AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the antiakinetic effect after I-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303–326 2 Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of 1-deprenyl to Madopar treatment of Parkinson's disease: a long-term study. J Neural Transm 1985; 64: 113–127 3 Knoll J. Extension of life span of rats by long-term (–)deprenyl treatment. Mt Sinai J Med 1988; 55: 67–74 4 Milgram NW, Racine RJ, Nellis P, et al. Maintenance of 1-deprenyl prolongs life in aged male rats. Life Sci 1990; 47: 415–420 5 Kitani K, Kanai S, Sato Y. et al. Chronic treatment of (–)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci 1993; 52: 281–288 6 Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984; 225: 1480–1482 7 Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 1984; 311: 467–469 8 Cohen G, Pasik P, Cohen B. et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) in monkeys. Eur J Pharmacol 1985; 106: 209–210 9 Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of l-methyl-4-Phenylpyridiniumion. J Neurochem 1985; 45: 1951–1953 10 Finnegan KT, Skratt JJ, Irwin I, et al. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 1990; 184: 119–126 11 Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991; 30: 666–677 12 Wu RM, Chieuh CC, Pert A, Murphy DL. Apparent antioxidant effect of 1-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 1993; 243: 241–247 13 Ansari KS, Yu PH, Kruck TPA, Tatton WG. Rescue of axotomized immature rat facial motoneurons by L-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993; 13: 4042–4053 14 Salo PT, Tatton WG. L-Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992; 31: 394–400 15 Tatton WG, Ju WYL, Holland DP, et al. (−)-Deprenyl reduces PC12 cell apoprosis by inducing new protein synthesis. J Neurochem 1994; 63: 1572–1575 16 Tarton WG, Ju WYH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promises for new approaches to neurological therapy. In: CW Olanow, P Jenner. MHB Youdim. eds. Neurodegeneration and neuroprotection. London: Academic Press, 1996: 202–220 17 Olanow CW, Hauser RA, Gauger L, et al. A longitudinal double blind controlled study of the affect of deprenyl and levodopa on the progression of the signs and symptoms of Parkinson's disease. Ann Neurol 1995; 38: 771–777 18 Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995; 311: 1602–1606 19 Calne DB. Selegiline in Parkinson's disease. Br Med J 1995; 311: 1583–1584 20 Olanow CW, Godbold J, Koller WC. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Br Med J 1996; 312: 702–703 21 Maki-Ikola O, Kilkku O, Heinonen E. Other studies have not shown increased mortality. Br Med J 1996; 312: 702 (Abstract) 22 Di Rocco A, Culliton DA. Yahr MD. Comparative mortality and longevity in parkinsonian patients treated with L-dopa alone or L-dopa and selegiline. Mov Disord 1996; 11: 189 (Abstract) 23 Ben Shlomo Y, Marmot MC. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995; 38: 293–299 24 Jellinger KA. Neurodegenerative disorders with extrapyramidal features—a neuropathological review. J Neural Transm 1995; 46: 33–56 25 Parkinson Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993; 307: 469–472 26 Haybittle JL. Repeated assessments of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 733–797 27 Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191–199 28 O'Brien PC, Fleming TR. A multiple resting procedure for clinical trials. Biometrics 1979; 35: 549–556 29 Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential trials. Controlled Clin Trials 1984; 5: 348–361 30 Tsiaris AA, Rosner GL, Mehta CR. Exact confidence intervals following a group sequential rest. Biometrics 1834; 40: 797–803 31 Coronary Drug Project Research Group. Practical aspects of decision making in clinical trials: the coronary drug project as a case study. Controlled Clin Trials 1981; 1: 363–376 32 Cox DR. Regression models and life tables. JRSS(B) 1972; 34: 187–220 33 Brannan T. Prikhojan A, Martinez-Tica J, Yahr MD. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-dopa and dopamine metabolism. J Neural Transm 1995; 10: 79–89 34 Wachtel SR, Abercrombie ED. L-3,4–Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treared rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 1994; 63: 108–117 34 Myllyla W, Heinonen E, Vuorinen JA, et al. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta Neurol Scand 1995; 91: 177–182 35 Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: Prado study discontinued. Eur J Clin Pharmacol 1992; 43: 357–363 36 Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc 1996; 71: 659–670 Citing Literature Volume40, Issue6December 1996Pages 841-845 ReferencesRelatedInformation